LGC and Q2 Solutions announce global bioanalytical strategic partnership
Ampersand-backed Alliance Pharma have now acquired LGC’s Drug Development Solutions Business (“DDS”).
LGC and Q2 Solutions, a leading clinical trial laboratory services organisation, announced today a global bioanalytical strategic partnership. The partnership provides Q2 Solutions’ customers with access to LGC’s bioanalytical facility, one of Europe’s largest dedicated bioanalytical services sites, and it provides LGC’s customers with access to the Q2 Solutions bioanalytical facilities in the US and China.
Q2 Solutions and LGC will each contribute their extensive experience and capabilities in small and large molecule bioanalysis to support a customer-centric approach. Given both organisations’ focus on delivering the highest quality science and services, customers can now enjoy a globally harmonised delivery of bioanalytical testing for their small- and large-molecule development programs.
“Over the last couple of years LGC has had a very positive experience collaborating together with Q2 Solutions on behalf of mutual clients”, said Michael van der Merwe, commercial director at LGC. “This reinforced the strategic, operational and cultural fit between our organisations and the decision to establish this partnership. We are looking forward to working with Q2 Solutions and deploying this global offering.”
“With LGC’s comprehensive bioanalytical center in Cambridge, UK, we see a synergistic fit between our organisations,” said Kevin Jones, vice president, general manager, Bioanalytical, ADME, and Vaccines Services, for Q2 Solutions. “This collaboration will offer our clients an expanded suite of bioanalytical capabilities and scientific expertise with an expanded global footprint operating from labs in the US, Europe and China.”
With more than twenty years working to GLP and GCP in one of the world’s most extensive bioanalytical facilities, LGC’s Drug Development Solutions team is dedicated to providing on time, high quality data to help make critical decisions on the safety and efficacy of small and large molecules in drug development.
LGC’s Cambridge, UK, facility is home to Centres of Excellence for Immunogenicity and Protein LC-MS. Supported by the latest mass spectrometry and immunochemistry technologies, the team has in-depth expertise in these key areas of bioanalytical science with successful contributions to biopharmaceutical research.